objeCtives: Nocturia is defined by the International Continence Society as the complaint of 'waking to void 1 or more times a night followed by sleep'. The most common cause is nocturnal polyuria (NP -nocturnal urine overproduction). While recognised as bothersome, it is often under-recognised as a separate condition and thus treated by medications for overactive bladder (OAB) or benign prostate hyperplasia (BPH), and not by an antidiuretic recommended for hormonal/renal dysfunctions, for example desmopressin. This analysis investigates the potential under-treatment of nocturia in a real world setting. Methods: Data were drawn from a 2013 crosssectional survey of physicians and consulting patients. Primary care physicians (264) and urology specialists (371) in France, Germany, Spain, UK and USA, actively managing urology patients, completed patient record forms prospectively for the next 14 OAB/BPH/nocturia patients who consulted. Results: Physicians provided records on 8738 patients, of which 569 had a primary diagnosis of nocturia or NP. There was substantial variation in treatment: 46% received an OAB treatment, 16% a BPH treatment, 7% other treatments, 21% no treatment, and 16% received desmopressin. There was considerable frequency in switching to second or third line treatments. After a mean of 16 months, 132 of the nocturia patients (23%) switched to a new treatment. Among these, 19% switched again after 13 months. Nocturia patients receiving desmopressin at some point were more likely to be satisfied with, and continue their current treatment, compared to those on BPH or OAB medications. ConClusions: The real-world survey suggests nocturia treatment is far from optimal in view of the need to frequently switch treatment modalities offering distinctly differing pharmacodynamic actions. Prescribing bladder or prostate medications for a renal condition, or withholding treatment, could potentially lead to considerable drug waste, extra physician visits, delay of most appropriate treatment and impaired quality of life. BresMed, Panjim, India, 3 Ferring Pharmaceuticals A/S, Copenhagen, Denmark objeCtives: Nocturia (getting up at night to void) can have a negative impact on quality of life (QoL), but limited data are available to determine the size of this impact. This study aimed to derive utility data on the impact of nocturia on QoL from the randomised clinical trial CS29 (clinicaltrials.gov; NCT00477490) for desmopressin versus placebo. Methods: SF-12 data collected at three time-points in CS29 (n= 803, male= 434, female= 369) were mapped to utility values using the SF-6D. Multiple data points were available per patient; a mixed model, with patient as a random effect variable, was therefore fitted using the generalised additive mixed model procedure in R. Utilities were produced accounting for the difference in various potentially clinical significant factors: age, body mass index, gender, number of co-morbidities, number of voids (NOV) and time to first void (TTV, also called first uninterrupted sleep period -FUSP). Diagnostic plots were produced to test model fit (scatter, residual and Q-Q), and Spearman rank correlations were calculated for all pairwise comparisons to test for multicollinearity in the data. For calculation of predictive utilities, all variables were set to their median values. Results: All diagnostic plots showed a good model fit and no violation of model assumptions. Though multicollinearity was found between NOV (median= 3.33 voids) and TTV (median= 1.78h), both variables were kept in the model to determine their relative impact on QoL. Both NOV and TTV had a significant impact on utility, with up to 0.1 change in score. The utility was 0.75, 0.72 and 0.69 for [0;2[, [2;4[ and [4;+∞[ voids per night, respectively . Age presented with the lowest utility score for patients aged 40-50. Male patients had a higher score than female patients. ConClusions: Nocturia severity has a significant impact on QoL. NOV and TTV can cause changes up to 0.1 in utility score. objeCtives: LUTS (lower urinary tract symptoms) are highly frequent and bothersome to the patient. Nocturia, defined by the International Continence Society as 4mg. The resulting incremental cost effectiveness ratio (ICER) was € 15,388/QALY gained. The probability of mirabegron 50 mg/day being cost-effective relative to tolterodine 4mg/day was 81.9% at a willingness to pay threshold of € 30,000/QALY. Incremental cost-effectiveness ratios of mirabegron 50mg/day versus solifenacin 5 and 10 mg/day were € 2,536 and € 4,837 per QALY gained, respectively. The probability of cost effectiveness for mirabegron 50mg/day was 90.0% and 90.5% versus solifenacin 5 and 10 mg/day respectively. Mirabegron 50mg/day was the dominant treatment (more effective with lower costs) versus fesoterodine 4 and 8 mg/day with a probability of cost-effectiveness of 93.8% and 93.1%, respectively. ConClusions: Mirabegron 50 mg/day is a cost-effective treatment compared with antimuscarinicagents in OAB patients from a Spanish NHS perspective. bACkgRound: Immunosuppresive therapy after organ transplantation is financed from federal budget in Russia, but only when certain drugs are prescribed, i.e. mycophenolic acid, mycophenolate mofetil, cyclosporine, tacrolimus. Everolimus had demonstrated good efficacy and safety in renal transplantation patients but has not been included into federal drug provision program yet. objeCtives: to calculate cost difference between two approaches for immunosuppressive therapy after renal transplantation: everolimus plus reduced-exposure cyclosporine (Ev+Cyc_red) and mycophenolic acid plus standard-exposure cyclosporine (MA+Cyc_st) for Russian healthcare system. Methods: We calculated the two-year difference in costs that resulted from efficacy and safety differences of compared alternatives employing the probability model. Data on safety and efficacy of compared strategies were taken from D. Cibrik et al. randomized control trial (2013) . Direct medical costs were calculated from the Russian healthcare system point of view. We also estimated the 5-year budget impact of everolimus inclusion into the drug provision program financed from federal budget. Results: Ev+Cyc_red leads to cost reduction by € 2.5 thousands (17%) per patient in a two-year period when compared to MA+Cyc_st. The reduction mainly results from less costs for immunosuppressive drugs in Ev+Cyc_ red approach compared to MA+Cyc_st. Also costs for cytomegalovirus infection prevention and treatment are smaller in Ev+Cyc_red strategy. Everolimus inclusion into federal drug provision program will lead to reduction in federal budget spending starting from the first year; the total five-year budget savings are € 4.3 million. ConClusions: Ev+Cyc_red is a cost-saving option for immunosuppressive therapy after renal transplantation in Russia when compared with MA+Cyc_st.
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Arun A, Pennington B BresMed Health Solutions Pvt. Ltd., Panjim, India objeCtives: Laparoscopic surgery is commonly used to remove the kidney from a donor in kidney transplant but was recently used for the first time in the UK to implant the kidney. The objective of this study was to analyse the costeffectiveness of using laparoscopic surgery compared to open surgery in kidney recipients. Methods: A decision tree model with a time-horizon of 10 days was constructed to capture short-term costs and benefits of patients undergoing kidney transplantation. The model was built from a third-party payer perspective in the UK. The costs for work-up, surgery, blood transfusion during surgery, equipment, hospital stay and post-operative complications were informed by National Health Service reference costs and published literature. The utilities for a patient during surgery (0.00), during recovery (0.48), with complications after surgery (0.40) and after being released from hospital (0.84) were derived from published literature. Results: The total costs for the laparoscopic surgery arm were lower than those for open surgery arm (£25,891 versus £25,962) -although the laparoscopic procedure itself was more expensive, the costs were offset by savings from reduced blood loss and lower risk of complications. The total quality adjusted life years (QALYs) were higher for laparoscopic surgery (0.01718 versus 0.01369) because of the lower number of days needed for recovery. At a threshold of £20,000 per QALY, the probability that laparoscopic surgery is cost effective was 0.595. The key drivers of the model were lengths of hospital stay after open and laparoscopic surgery and duration of laparoscopic surgery. The incremental cost effectiveness ratio was dominant in the base case but could be as high as £78,468 if risk of complications after open surgery decreases from 0.512 to 0.368. ConClusions: This study suggests that the laparoscopic surgery improves quality of life at a lower cost, but is subject to uncertainty.
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Giotta N, Marino AM Cardinal Massaia Hospital, ASTI, Italy objeCtives: The objective of this study is to evaluate the difference in terms of efficacy and costs of lanthanum carbonate plus standard therapy (LTS) compared to standard therapy alone (TS) in the treatment of hemodialysis patients with persistent hyperphosphatemia. Methods: We selected 14 consecutive patients (8 males and 7 females) on hemodialysis with more than four phosphorus values greater than 6 mg/dL in three months, got them recruited in therapy with lanthanum carbonate. The data analysis has been done considering a phase retrospective (FR) of three months and a phase perspective (FP) of six months, analyzing for each subject consumption and the effectiveness of therapy before and after enrollment. The effectiveness of treatment, was evaluated as the percentage of patients who
